AZ Considers Filings for Long-Acting Strensiq Follow-Up

Why It Matters

The launch could extend AZ’s revenue stream beyond Strensiq’s patent cliff and offer patients a less burdensome dosing schedule, potentially reshaping the ultra‑rare HPP treatment landscape. It also signals heightened competition in enzyme replacement therapies for rare bone disorders.

Key Takeaways

• AZ plans long‑acting efzimfotase alfa follow‑up to Strensiq.
• Pediatric trials met endpoints; adolescent/adult trial missed primary goal.
• Biweekly injection could replace weekly Strensiq dosing.
• HICKORY trial showed trend in 6MWT, fatigue improvement.
• Competition emerging from AM Pharma’s ilofotase alfa phase‑1b.

Pulse Analysis

Hypophosphatasia (HPP) remains one of the most challenging ultra‑rare metabolic disorders, affecting bone mineralization and causing systemic complications. Since its approval over a decade ago, Strensiq has dominated the market, delivering $1.68 billion in annual sales and becoming the sole therapy specifically indicated for HPP. However, its weekly subcutaneous regimen and looming patent expiration in the early 2030s have spurred AstraZeneca’s Alexion unit to pursue a next‑generation solution that can sustain market leadership while addressing patient convenience.

The phase 3 program for efzimfotase alfa delivered a mixed picture. In the pediatric MULBERRY trial, the drug achieved its primary bone‑health endpoints, and the open‑label CHESTNUT study demonstrated a seamless switch from Strensiq, preserving therapeutic benefit. Conversely, the HICKORY trial in adolescents and adults missed its primary six‑minute walk test outcome, though a nominally significant fatigue improvement emerged. The prospect of a biweekly injection—half the frequency of Strensiq—could dramatically reduce treatment burden, a compelling advantage if efficacy gaps can be narrowed in future studies.

Strategically, a successful filing would extend AstraZeneca’s revenue horizon beyond Strensiq’s patent cliff, reinforcing its foothold in rare‑disease therapeutics. At the same time, emerging competitors like AM Pharma’s ilofotase alfa, now in phase 1b, signal an intensifying pipeline of enzyme replacement candidates. Investors and clinicians will watch closely as AZ balances regulatory submissions, additional data generation, and market dynamics to determine whether efzimfotase alfa can become the new standard of care for both pediatric and adult‑onset HPP.